Clinical Trials Logo

Gynecologic Cancer clinical trials

View clinical trials related to Gynecologic Cancer.

Filter by:
  • Withdrawn  
  • Page 1

NCT ID: NCT05689359 Withdrawn - Breast Cancer Clinical Trials

Evaluation of Hydroxychloroquine to Prevent CIPN

Start date: June 2024
Phase: Phase 2
Study type: Interventional

The study is being done to research if hydroxychloroquine can prevent chemotherapy induced peripheral neuropathy. Certain chemotherapy drugs, like paclitaxel, are known to cause neuropathy which can impact quality of life. Currently, there are no options for preventing peripheral neuropathy. In addition, there are no useful methods to assess peripheral nerve damage. This study will also explore using a study MRI of patients' feet prior to starting chemotherapy and after they have completed chemotherapy to see if there is any difference in their nerve structure.

NCT ID: NCT05466916 Withdrawn - Gynecologic Cancer Clinical Trials

EDITS Pilot Study for Gynecologic Cancer Survivors

Start date: July 20, 2022
Phase: N/A
Study type: Interventional

The main goal in this project is to develop and pilot test a 12-week multiple health behavior change (MHBC) intervention for feasibility and acceptability. The pilot study will be guided by Multiphase Optimization Strategy (MOST) framework, which uses highly efficient experiments to systematically test and compare intervention components' or component levels' individual and combined effects. The goal of the MOST framework is to balance effectiveness with affordability, sustainability, and efficiency.

NCT ID: NCT05365243 Withdrawn - Breast Cancer Clinical Trials

A Pilot Study to Evaluate the Use of the AMMA Portable Scalp Cooling System From Cooler Heads

Start date: August 15, 2022
Phase: N/A
Study type: Interventional

Eligible patients will be recruited prior to initiation of chemotherapy for any stage breast or gynecologic cancer. Patients will undergo training in the use of the AMMA Portable Scalp Cooling System and will use the device during each of their chemotherapy treatments. Quality of life and experience of use questionnaires will be completed. Scalp photos and an assessment of hair loss will be preformed at enrollment and at the end of study participation.

NCT ID: NCT04630483 Withdrawn - Cancer Clinical Trials

Platelet-lymphocyte and Neutrophil-lymphocyte Ratio in Patients Undergoing Cancer Surgery

Start date: November 23, 2020
Phase:
Study type: Observational [Patient Registry]

Cancer is a major cause of morbidity and mortality worldwide. Despite the use of surgery in an attempt to cure the majority of solid tumors, metastasis from residual cancer cells still remains a major cause of morbidity and mortality. General anesthesia and surgical stress during surgery suppress the immune response by directly affecting the immune system or by activating the hypothalamic-pituitaryadrenal axis and the sympathetic nervous system. The aim of our prospective observational study was to assess the value of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio regarding outcome underwent cancer surgery. Primary aim is to assess the preoperative and postoperative values of inhalational anesthesia vs total intravenous anesthesia.

NCT ID: NCT04368130 Withdrawn - Ovarian Cancer Clinical Trials

SIGNAL:Identifying Behavioral Anomalies Using Smartphones to Improve Cancer Care

SIGNAL
Start date: September 1, 2022
Phase: N/A
Study type: Interventional

This research study is testing the use of a smartphone app to identify clinically meaningful changes in the behaviors of patients' with gynecological cancers by using passively collected smartphone data.

NCT ID: NCT02067637 Withdrawn - Breast Cancer Clinical Trials

Delayed Effects of Treatment in Cancer Survivors (DETECS)

DETECS
Start date: March 2014
Phase: N/A
Study type: Observational

Hypotheses and Specific Aims: There is limited data on the long-term consequences of cancer therapy on young, reproductively aged cancer survivors. The investigators objective is to characterize some of these effects in the cancer population.